Global-feature of autoimmune glomerulonephritis using proteomic analysis of laser capture microdissected glomeruli

Background IgA nephropathy (IgAN), (LN), membranous nephropathy (MN), and minimal change nephropathy (MCN) are all belonged to autoimmune glomerulonephritis. This study aimed to identify the specific proteomic characteristics of the four GNs diseases in order to provide frameworks for developing the appropriate drug for patients diagnosed with GNs disease. Methods Liquid chromatography−tandem mass spectrometry (LC-MS/MS) was utilized to investigate proteomic features of glomerular tissues obtained by laser capture microdissection (LCM). 8 normal control cases, 11 IgAN cases, 19 LN cases, 5 MN cases, and 3 MCN cases in this study were selected for bioinformatics analyses. Results The shared overlapping proteins among the top 100 DEPs of each GNs type were mostly downregulated, in which only FLII was significantly downregulated in the four GNs diseases. A2M was significantly upregulated in MN, IgAN, and LN subgroups. The pathway of complement and coagulation cascades was notably activated with NES value ranging 2.77 to 3.39 among MCN, MN, IgAN, and LN diseases, but the pattern of protein expression level were significantly different. In LN patients, the increased activity of complement and coagulation cascades was contributed by the high expression of multiple complements (C1QB, C3, C4A, C4B, C6, C8B, C8G, C9). Meanwhile, both C1QC and C4B were remarkably upregulated in MN patients. On the contrary, complement-regulating proteins (CD59) was substantially decreased in MCN and IgAN subgroup. Conclusions The integrative proteomics analysis of the four GNs diseases provide insights into unique characteristics of GNs diseases and further serve as frameworks for precision medicine diagnosis and provide novel targets for drug development.

[1]  W. Davis,et al.  Retinopathy prevalence, incidence and trajectories in type 2 diabetes: The Fremantle diabetes study phase II , 2022, Diabetic medicine : a journal of the British Diabetic Association.

[2]  C. Schmidt,et al.  Protein therapeutics and their lessons: Expect the unexpected when inhibiting the multi‐protein cascade of the complement system , 2022, Immunological reviews.

[3]  B. Rovin,et al.  Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. , 2021, Kidney international.

[4]  A. Kronbichler,et al.  Advances in Understanding of Pathogenesis and Treatment of Immune-Mediated Kidney Disease: A Review. , 2021, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  Yingwei Wang,et al.  Sublytic C5b-9 induces glomerular mesangial cell proliferation via ERK1/2-dependent SOX9 phosphorylation and acetylation by enhancing Cyclin D1 in rat Thy-1 nephritis , 2021, Experimental & Molecular Medicine.

[6]  J. N. van den Anker,et al.  Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway , 2020, Frontiers in Immunology.

[7]  Xuejun Zhang,et al.  Quantitative proteomics analysis of young and elderly skin with DIA mass spectrometry reveals new skin aging-related proteins , 2020, Aging.

[8]  N. Sheerin,et al.  The role of complement in kidney disease. , 2020, Clinical medicine.

[9]  Paul J. Hoover,et al.  Single cell transcriptomics identifies focal segmental glomerulosclerosis remission endothelial biomarker. , 2020, JCI insight.

[10]  Simon Youssef,et al.  Quantitative modeling of synthetic gene transfer , 2011 .

[11]  H. Debiec,et al.  Molecular Pathogenesis of Membranous Nephropathy. , 2020, Annual review of pathology.

[12]  S. Cha,et al.  Inhibition of the ERK1/2-mTORC1 axis ameliorates proteinuria and the fibrogenic action of transforming growth factor-β in Adriamycin-induced glomerulosclerosis. , 2019, Kidney international.

[13]  Z. Kopecki,et al.  Flightless I exacerbation of inflammatory responses contributes to increased colonic damage in a mouse model of dextran sulphate sodium-induced ulcerative colitis , 2019, Scientific Reports.

[14]  P. Cutillas,et al.  Perineural invasion in pancreatic cancer: proteomic analysis and in vitro modelling , 2019, Molecular oncology.

[15]  W. Sandoval,et al.  Discovery and Qualification of Candidate Urinary Biomarkers of Disease Activity in Lupus Nephritis. , 2018, Journal of proteome research.

[16]  Ming-hui Zhao,et al.  Complement in glomerular diseases , 2018, Nephrology.

[17]  Thomas Stoll,et al.  Identification of Novel Circulating Biomarkers Predicting Rapid Decline in Renal Function in Type 2 Diabetes: The Fremantle Diabetes Study Phase II , 2017, Diabetes Care.

[18]  F. Berven,et al.  Glomerular abundance of complement proteins characterized by proteomic analysis of laser-captured microdissected glomeruli associates with progressive disease in IgA nephropathy , 2017, Clinical Proteomics.

[19]  B. Ueberheide,et al.  Proteomic differences in amyloid plaques in rapidly progressive and sporadic Alzheimer’s disease , 2017, Acta Neuropathologica.

[20]  Ming-hui Zhao,et al.  Complement Alternative Pathway's Activation in Patients With Lupus Nephritis , 2017, The American journal of the medical sciences.

[21]  F. Kronenberg,et al.  Association between apolipoprotein A‐IV concentrations and chronic kidney disease in two large population‐based cohorts: results from the KORA studies , 2015, Journal of internal medicine.

[22]  R. Arkell,et al.  Fibroblast‐specific upregulation of Flightless I impairs wound healing , 2015, Experimental dermatology.

[23]  D. Bubeck The making of a macromolecular machine: assembly of the membrane attack complex. , 2014, Biochemistry.

[24]  G. Xing,et al.  C3a, C5a Renal Expression and Their Receptors are Correlated to Severity of IgA Nephropathy , 2014, Journal of Clinical Immunology.

[25]  T. Takano,et al.  Complement-mediated cellular injury. , 2013, Seminars in nephrology.

[26]  D. Zillikens,et al.  Topically applied flightless I neutralizing antibodies improve healing of blistered skin in a murine model of epidermolysis bullosa acquisita. , 2013, The Journal of investigative dermatology.

[27]  Y. Itoyama,et al.  Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica , 2013, Journal of Neuroimmunology.

[28]  Anjali A. Satoskar,et al.  A quantitative proteomic workflow for characterization of frozen clinical biopsies: laser capture microdissection coupled with label-free mass spectrometry. , 2012, Journal of proteomics.

[29]  Wuding Zhou,et al.  The role of complement in the early immune response to transplantation , 2012, Nature Reviews Immunology.

[30]  R. Liddington,et al.  Crystal Structure of C5b-6 Suggests Structural Basis for Priming Assembly of the Membrane Attack Complex* , 2012, The Journal of Biological Chemistry.

[31]  W. Couser Basic and translational concepts of immune-mediated glomerular diseases. , 2012, Journal of the American Society of Nephrology : JASN.

[32]  D. Zillikens,et al.  Overexpression of the Flii gene increases dermal–epidermal blistering in an autoimmune ColVII mouse model of epidermolysis bullosa acquisita , 2011, The Journal of pathology.

[33]  C. Cudrici,et al.  TRAIL, DR4 and DR5 are upregulated in kidneys from patients with lupus nephritis and exert proliferative and proinflammatory effects. , 2009, Clinical immunology.

[34]  Chunli Shao,et al.  The roles of MAPKs in disease , 2008, Cell Research.

[35]  P. Gasque,et al.  Extrahepatic complement biosynthesis: where, when and why? , 1997, Clinical and experimental immunology.

[36]  W. Couser,et al.  Elevated urinary excretion of the C5b-9 complex in membranous nephropathy. , 1991, Kidney international.

[37]  Robert C. Wolpert,et al.  A Review of the , 1985 .